STATISTICAL ANALYSIS PLAN
Study Title: A Phase 1b, Randomized, Double- Blind, Placebo- controlled 
Study  to Evaluate the Safety  and Efficacy  of GS -9620 in 
Antiretroviral Treated HIV -1Infected Controllers
Name of Test Drug: Vesatolimod (VES; GS - 9620)
Study Number: GS-US-
382-3961
Protocol Version (Date) : Amendment 4: 05 February 2019
Analysis Type: Final Anal ysis
Analysis Plan Version: Version 1.0
Analysis Plan Date: 17March 2020
Analysis Plan Author:
CONFIDENTIAL AND PRO PRIETARY INFORMATION
PPD(rJ GILEAU 
VES
GS-US-382-3961
Statistical Analysis Plan (Final Analysi s) Version 1.0
CONFIDENTIAL Page 2 17March 2020TABLE OF CONTENTS
TABLE OF CONTENTS .............................................................................................................................................. 2
PHARMACOKINETIC ABBR EVIATIONS ................................................................................................................ 7
1. INTRODUCTION ................................................................................................................................................ 8
1.1. Study Objectives ...................................................................................................................................... 8
1.2. Study Design .......................................................................................................................................... 10
1.3. Sample Size and Pow er.......................................................................................................................... 12
2. TYPE OF PLANNED ANAL YSIS .................................................................................................................... 13
2.1. Interim Analyses .................................................................................................................................... 13
2.1.1. Interim Blinded Analyses ..................................................................................................... 13
2.1.2. Interim Unblinded Analyses ................................................................................................. 13
2.2. Final Analysis ........................................................................................................................................ 13
3. GENERAL CONSIDERATIO NS FOR DATA ANALYSES ............................................................................ 14
3.1. Analysis Sets .......................................................................................................................................... 14
3.1.1. All Randomized Analysis Set ............................................................................................... 14
3.1.2. Full Analysis set ................................................................................................................... 14
3.1.3. Safety Analysis Set ............................................................................................................... 14
3.1.4. VES Pharmacokinetic Analysis Set ...................................................................................... 15
3.2. Subject Grouping ................................................................................................................................... 15
3.3. Strata and Covariates .............................................................................................................................. 15
3.4. Examination of Subject Subgroups ........................................................................................................ 15
3.5. Multiple Comparisons ............................................................................................................................ 15
3.6. Missing Data and Outliers ...................................................................................................................... 16
3.6.1. Missing Data ........................................................................................................................ 16
3.6.2. Outliers ................................................................................................................................. 16
3.7. Data Handling Conventions and Transformations ................................................................................. 16
3.8. Analysis Visit Windows ......................................................................................................................... 17
3.8.1. Definition of Study Day ....................................................................................................... 17
3.8.2. Analysis Visits ...................................................................................................................... 18
3.8.3. Selection of Data in the Event of Multiple Records for a Visit ............................................ 18
4. SUBJECT DISPOSITION .................................................................................................................................. 19
4.1. Subject Enrollment and Disposition ....................................................................................................... 19
4.1.1. Subject Enrollment ............................................................................................................... 19
4.1.2. Subject Disposition .............................................................................................................. 19
4.2. Extent of Exposure ................................................................................................................................. 19
4.3. Protocol Deviations ................................................................................................................................ 20
5. BASELINE CHARACTERIS TICS .................................................................................................................... 21
5.1. Dem ographics and Baseline Characteristics .......................................................................................... 21
5.2. Baseline Disease Characteristics ............................................................................................................ 21
5.3. Medical History ...................................................................................................................................... 21
6. EFFICACY ANALYSES ................................................................................................................................... 22
6.1. Definition of Efficacy Endpoints ........................................................................................................... 22
6.2. Statistical Hypotheses for Efficacy Endpoints ....................................................................................... 22
6.3. Analysis of Efficacy Endpoints .............................................................................................................. 22
7. SAFETY ANALYSES ........................................................................................................................................ 24
VES
GS-US-382-3961
Statistical Analysis Plan (Final Analysi s) Version 1.0
CONFIDENTIAL Page 3 17March 20207.1. Adverse Events and Deaths .................................................................................................................... 24
7.1.1. Adverse Event Dictionary .................................................................................................... 24
7.1.2. Adverse Event Severity ........................................................................................................ 24
7.1.3. Relationship of Adverse Events to Study Drug .................................................................... 24
7.1.4. Relationship of Adverse Events to Study Procedure ............................................................ 24
7.1.5. Serious Adverse Events ........................................................................................................ 24
7.1.6. Treatment- Emergent Adverse Events ................................................................................... 25
7.1.6.1. Definition of Treatment -Emergent Adverse Events ....................................... 25
7.1.6.2. Incomplete Dates ............................................................................................ 25
7.1.7. Summaries of Adverse Events and Deaths ........................................................................... 25
7.1.8. Additional Analysis of Adverse Events ............................................................................... 26
7.2. Laboratory Evaluations .......................................................................................................................... 27
7.2.1. Summaries of Numeric Laboratory Results ......................................................................... 27
7.2.2. Graded Laboratory Values ................................................................................................... 27
7.2.2.1. Treatment- Emergent Laboratory Abnormalitie s............................................. 28
7.2.2.2. Summaries o f Laboratory Abnormalities ........................................................ 28
7.3. Body  Weight, Height, BMI and Vital Signs ........................................................................................... 28
7.4. Prior and Concomitant Medications ....................................................................................................... 29
7.4.1. Antiretroviral Medications ................................................................................................... 29
7.4.2. Prior Antiretroviral Medications .......................................................................................... 29
7.4.3. Concomitant Non-Antiretroviral Medications ...................................................................... 29
7.5. Electrocardiogram Results ..................................................................................................................... 30
7.6. Other Safety Measures ........................................................................................................................... 30
7.7. Changes From Protocol -Specified Safety Analyses ............................................................................... 30
8. PHARMACOKINETIC ANAL YSES ................................................................................................................ 31
8.1. PK Sample Collection ............................................................................................................................ 31
8.2. PK Analyses Related to Intensive PK Sampling .................................................................................... 31
8.2.1. Estimation of Pharmacokinetic Parameters .......................................................................... 31
8.2.2. PK Parameters ...................................................................................................................... 31
8.3. Statistical Analysis Methods .................................................................................................................. 32
9. PHARMACODYNAMIC (PD) ANALYSES ..................................................................................................... 33
9.1. Definition of PD Endpoints .................................................................................................................... 33
9.2. Analysis of PD Endpoints ...................................................................................................................... 33
10. REFERENCES ................................................................................................................................................... 34
11. SOFTWARE ....................................................................................................................................................... 35
12. SAP REVISION .................................................................................................................................................. 36
13. APPENDICES .................................................................................................................................................... 37
Appendix 1. PK Parameters ........................................................................................................................ 37
Appendix 2. Schedule of Assessments ........................................................................................................ 38
Appendix 3. Programming Specification .................................................................................................... 43
VES
GS-US-382-3961
Statistical Analysis Plan (Final Analysi s) Version 1.0
CONFIDENTIAL Page 4 17March 2020LIST OF IN- TEXT TABLES
Table 8-1. PK Parameters for VES .......................................................................................................... 31
VES
GS-US-382-3961
Statistical Analysis Plan (Final Analysi s) Version 1.0
CONFIDENTIAL Page 5 17March 2020LIST OF ABBREVIATIONS
AE adverse event
ALT alanine aminotransferase
ANOVA analysis of variance
ART antiretroviral therapy
ARV antiretroviral
AST aspartate aminotransferase
BL baseline
BLQ below  the limit of quantification
BMI body mass index
CAVR/CAVD cell-associated HIV -1 RNA/DNA
CRF case report form
CSR clinical study report
DLTs dose- limiting toxicities
DMC data monitoring committee
ECG electrocardiogram
ESDD early study drug discontinuation
eCRF electronic case report form 
FU follow -up
GLSM geometric least -squares means 
GSI Gilead Sciences, Inc
HLT high level term
HLGT high level group term
ICS intracellular cytokine staining 
ISGs interferon -stimulated genes 
IVRS interactive voice response system
IWRS interactive web response system
LLOQ lower limit of quantitation
LLT lower level term
LOQ limit of quantita tion
MAD multiple ascending dose
MedDRA medical dictionary for regulatory activities
PBMC peripheral blood mononuclear cell
PT preferred term
PVE Pharm acovigilance and Epidemiology
Q1 first quartile
VES
GS-US-382-3961
Statistical Analysis Plan (Final Analysi s) Version 1.0
CONFIDENTIAL Page 6 17March 2020Q3 third quartile
SAE serious adverse event
SAP statistical analysis plan
SCA single copy assay
SD standard deviation
SEC safety evaluation committee 
SOC system organ class
TEAE treatment -emergent adverse event
TFLs tables, figures, and listings
ULN Upper limit of normal
ULOQ upper limit of quantification
VES (GS -
9620)Vesatolimod
WHO World Health Organization
VES
GS-US-382-3961
Statistical Analysis Plan (Final Analysi s) Version 1.0
CONFIDENTIAL Page 7 17March 2020PHARMACOKINETIC ABBR EVIATIONS
AUC last area under the concentration versus time curve from time zero to the last quantifiable 
concentration
AUC inf area under the concentration versus time curve extrapolated to infinite time, calculated as 
AUC 0-last(Clast/z)
%AUC exp Percentage of AUC extrapolated betw een AUC 0-last and AUC inf
Clast last observed quantifiable concentration of the drug in plasma
Cmax maximum observed concentration of drug in plasma
CL/F apparent oral clearance af ter administration of the drug:
at single dose: CL/F =Dose/AUC inf , where “Dose” is the dose of the dru
T1/2 estimate of the terminal elimination half -life of the drug in plasma, calculated by dividing the 
natural log of 2 by the terminal elimination rate constant ( z)
Tlast time (observed time point) of C last
Tmax time (observed time point) of C max
Vz/F apparent volume of distribution of the drug
z terminal elimination rate constant, estimated by linear regression of the terminal elimination 
phase of the concentration of drug versus time curve
VES
GS-US-382-3961
Statistical Analysis Plan (Final Analysi s) Version 1.0
CONFIDENTIAL Page 8 17March 20201. INTRODUCTION
This statistical analy sis plan (SAP) describes the statistical analy sis methods and data 
presentations to be used in tables, figures, and listings (TFLs) in the clinical study  report (CSR) 
for Study  GS-US- 382- 3961 . This SAP is based on the study  protocol A mendment 4dated 
05February 2019 and the electronic case report form (eCRF). The SAP will be finalized before 
database finalization for the final anal ysis. Any changes made after the finalization of the SAP 
will be documented in the CSR.
1.1. Study Objectives
The primary objective sof this study  areas follows:
To evaluate the safet y and tolerability of a 10 -dose regimen of vesatolimod (VES; previously  
referred to as GS-9620) in HIV - 1 infected controllers on antiretroviral treatment (ART) and 
during anal ytical treatment interruption (ATI) following VES dosing
The secondary  objectives of this study  areas follows:
Virology
To evaluate the effect of VES in reactivating the HIV -1 reservoir, as measured by  changes in 
plasma HIV -1 RNA b y Taqman 2.0
To evaluate the effect of VES in modulating time to virologic rebound and plasma viral load 
set-point followin g ATI
Immunology /Pharmacody namics
To evaluate the pharmacody namics (PD) of VES as measured b y changes in serum/plasma
cytokines, and mRNA of interferon
-stimulated genes (ISGs) in whole blood
To evaluate effects of VES on immune cell activation in whole blood
Pharmacokinetics
To evaluate the plasma pharmacokinetics (PK) of VES
CCI
I 
YES 
GS-US-382-3961 
Statistical Analysis Plan (Final Analysis) -I 
I 
I 
I 
I 
I 
I 
I 
CON FIDENT IAL Version 1.0 
Page 9 17 March 2020 
YES 
GS-US-382-3961 
Statistical Analysis Plan (Final Analysis) 
1.2. Study Design Version 1.0 
This is a phase 1 b, random ized, doub le-blind, placebo-contro lled study w ith a single cohort of 
HIV-1 infected contro llers on ART w ith a history of pre-ART plasma HIV-1 RNA between 
50 and :S 5000 copies/mL. 
Randomization was strat ified by pre-ART viral load (~ 50 to< 2000 copies/mL or~ 2000 to 
:S 5000 copies /mL) at scree ning. Subjects were random ized in a 2: 1 ratio to receive YES or 
placebo-to-match . 
The study was conducted in three periods. In Period 1, up to 30 subjects were random ized 2: 1 to 
receive YES or placebo-to-match . All subjects received up to 10 doses of their assigned study 
treatment admin istered orally every 14 days only in Period 1. Subjects cont inued to take their 
prescr ibed ART during Period 1. 
In Period 2, all subjects discont inued ART and were monitor ed for rebom1d in HIV-1 plasma 
viremia for 24 weeks of close observat ion and follow up. 
If subjects restarted ART at the start of Period 3, subjects comp leted ART Re-Initiation V isits, 
and then Post ART Re-Suppress ion Visits monthly for 6 additiona l month s (Post ART 
Re-Suppress ion Visits 1-6). For these subjects, the last study visit was the Post ART 
Re-Suppress ion Visit 6. 
Dosing of YES occurred 14 days apart starting at Dose 1-Day 1, Dose 2-Day 1, Dose 3-Day 1, 
Dose 4-Day 1, Dose 5-Day 1, Dose 6-Day 1, Dose 7-Day 1, Dose 8-Day 1, Dose 9-Day 1 and 
Dose 10-Day 1 visi ts respect ively. Subjects fasted for at least 2 hours (preferab ly overn ight) 
before dosing. Subjects were also asked to prov ide infonnat ion on food consumpt ion and total 
fasting time prior to dosing. 
Laboratory analyses (hematolo 
visits, monthly during Period 2 , and urina lysis) were perfonned at all dosing 
, post ART Re-suppress ion Visits 
and Early Study Drug Discont inuation (ESDD) Visit. 
Urin e pregnancy test (for fema les of childbear ing potent ial) was perfonne ~ t 
ATI visit 1 (ATI start visit), at every other visit thereafter durin g Period 2, _ 
_ , at first ART Re-initiation visit and monthl y thereafter until Post ART Re-Suppress ion 
Visit 1, post ART Re-suppress ion Visits and End of Study Visi t. 
Vital signs (blood pressure, pulse, respiration rate and tern erature 
visits and every other week during Period 2 
CONFI DENT IAL Page 10 17 March 2020 
YES 
GS-US-382-3961 
Statistical Analysis Plan (Final Analysis) 
Plasma HIV-1 RNA was meas ured at every visit. Cell-associated HI V-1 RNA/DNA Vers ion 1.0 
(CA VR/CA VD) from PBMC s was meas ured at Pre-baseline/Day -13 and within 1 hour before 
and 1 and 3 days after Doses 4 and 10, within 1 hour before and 3 days after Dose 6, 
Dose 10-Day 14, ATI Remi ssion Visit and at Post-AR T re-suppr ession Visit 6 (6 month s 
post-AR T virologic re-s uppr ession). Plas ma HIV-1 RNA Single Copy Assay (SCA ) was 
collected at Pre-Baseline/Day -13, within 1 hour before, and 1 and 3 days after Doses 4 and 10, 
within 1 hour before and 3 days after Dose 6, Dose 10-Day 14, ATI Remi ssion Visit and 
Post-AR T re-su r ession Visit 6 6 month s os t-AR T virolo ic r e-su r ession . 
Chan ges in the levels of serum/plas ma 
cyto mes c emo mes y nmnunoa ssays were meas ured wi thin 1 hour before and 1 and 7 days 
after Doses 1, 4, and 10, and ATI Remi ssion Visit. 
Assess ments of adverse events and concom itant medi cations were perfonn ed at each visit. 
Symptom-dir ected physical examination was pe rfonn ed at every visit during Peri od 1. Complete 
physical examination was perfonn ed once a month and symptom directed h si cal examination 
on other visi ts was pe rfonn ed every two weeks during Peri od 2 -· Blood samples were collected to detennine plas ma VES conc entrat ions and plasma ART 
conc entration s at the following ti me points relative to study drug dosing: 
CON FIDENTIAL Page 11 17 March 2020 
VES
GS-US-382-3961
Statistical Analysis Plan (Final Analysi s) Version 1.0
CONFIDENTIAL Page 12 17March 2020Plasma VES concentrations at the following time points:
Pre-dose ( ≤5 minutes prior to dosing), 0.5, 1, 2, 4, 6, 8, 10, and 24 hours post dose at 
Dose 1-Day 1 visit.
Plasma ARV concentrations :
a single trough ARV PK sample w ascollected at Screening. Another single t rough PK sample 
wascollected at Dose 6 Day 4.
1.3. Sample Size and Power
No power calculation was performed because this wasan exploratory  study to characterize the 
safet y and efficacy of VES .
VES
GS-US-382-3961
Statistical Analysis Plan (Final Analysi s) Version 1.0
CONFIDENTIAL Page 13 17March 20202. TYPE OF  PLANNED ANAL YSIS
2.1. Interim Analyses
2.1.1. Interim Blinded Analyses
A Safet y Evaluation Committee (SEC)review edthe progress of the study  and perform edinterim 
reviews of the safety data in order to protect subject welfare and preserve study  integrit y. To 
ensure the best interests of the participants, the SEC recommend edto the sponsor if the nature, 
frequency , and severit y of adverse effects associated with the study  treatment warrant edthe earl y 
termination of the study , the continuation of the study , or the continuation of the study with 
modifications.
The initial meet ing of the SEC occurred through email prior to the first dose of the stud y. This 
meeting formall y established the SEC and thoroughly acquainted the SEC with the protocol and 
the SEC Charter. Subsequent SEC analy siswasperformed after half of the subjects hadreceived 
four doses of VES or placebo -to-match.
The SEC’s role and responsibilities and the scope of anal ysis to be provided to the SEC we re 
provided in a mutually agreed upon charter, which define d the SEC membership, meeting 
logistics, and meeting fr equency .
2.1.2. Interim Unblinded Analy ses
Prior to the final anal ysis, a few selected individuals from Gilead were unblinded to assess the
interim safet yand virology data of VES . This group may have consist edof at least one 
representative from Clinical Research, Biostatistics, Clinical Pharmacology, 
Pharmacovigilance/Epidemiology , Biomarkers, and Clinical Virology . Details of unblinding 
(eg,memberships, responsibilit ies, analy sis schedules) were defined in a n Internal Data R eview 
Team Charter .
After at least 10 subjects complete dATI Week 24 or met criteria to restart ART , the Sponsor 
conducted interim unblinded anal yses to revi ew the data as described above. The results from 
these anal yses were submitted to regulatory  agenci es to facilitate the clinical development 
program, presented externally  or published to disseminate the findings.
2.2. Final Analysis
After all subjects had completed the study , outstanding data queries resolved or adjudicated as 
unresolvable, and the data had been cleaned and finalized, the study  blind will be broken and the
final anal ysis of the data will be performed.
VES
GS-US-382-3961
Statistical Analysis Plan (Final Analysi s) Version 1.0
CONFIDENTIAL Page 14 17March 20203. GENERAL  CONSIDERA TIONS FOR DA TA ANAL YSES
Analy sis results will be presented using descriptive statistics. For categorical variables, the 
number and percentage of subjects in each category  will be presented; for continuous variables, 
the number of subjects (n), mean, standard deviation (SD) or sta ndard error (SE), median, 
firstquartile (Q1), third quartile (Q3), minimum, and maximum will be prese nted.
All statistical tests will be 2 -sided and performed at the 5% significance level unless otherwise 
specified.
By-subject listings will be presented for all subjects in the All Randomized Analy sis Set and 
sorted by  subject ID number, visit date, and time (if applicable) , unless specified otherwise . Data 
collected on log forms, such as AEs, will be presented in chronological order within the subject. 
The treatment group to which subjects were randomized will be used in the listings. Age, sex at 
birth, race, and ethnicit y will be included in the listings, as space permits. In addition, 3 subjects 
rolled over from Study  GS-US- 382- 1450 to the ATI  phase of Study  GS-US- 382- 3961. They  will 
be included in the listings.
3.1. Analysis Sets
Analy sis sets define the su bjects to be included in an anal ysis. Anal ysis sets and their definitions
are provided in this section. Subjects included in each anal ysis set will be determined before the 
study  blind is broken for anal ysis.The anal ysis set will be identified and include d as a subtitle of 
each table, figure, and listing. A summary  of the number and percentage of subjects in each 
analysis set will be provided by treatment group.
3.1.1. All Randomized Analysis Set
The All Randomized Analy sis Set includes all subjects who were randomized in tothe study .
This is the primary  anal ysis set for by -subject listings.
3.1.2. Full Analysis set
The Full Analysis Set (FAS) will include all subjects who (1) were randomized into the study  
and (2) received at least one dose of stud y drug. Subjects will be grouped according to the 
treatment to which they  were randomized. For the FAS, all efficacy  data, including data 
collected after the last dose of study  drug, will be included, unless specified otherwise. This is 
the primary  analy sis set for efficacy  analyses.
3.1.3.
Safety Analysis Set
The Safet y Analysis Set will include all subjects wh o (1) were randomized into the study  and 
(2)received at least 1 dose of study  drug. For the safet y analysis set , all safety data, including 
data collected after the last dose o f study  drug, will be included, unless specified otherwise.
Subjects will be grouped according to the treatment they  actually  received. This is the primary  
analysis set for safet y analyses.
VES
GS-US-382-3961
Statistical Analysis Plan (Final Analysi s) Version 1.0
CONFIDENTIAL Page 15 17March 20203.1.4. VES Pharmacokinetic Analysis Set
The VES PK Analysis Set will incl ude all subje cts who (1) were randomized into the study , 
(2)received at least 1 dose of active VES , and (3) have at least 1 nonmissing postbaseline 
concentration value for VES . This is the primary  anal ysis set for detailed PK anal ysis of 
intensive PK sampling.
3.2. Subject Grouping
For analy ses based on the All Randomized Analysis Set or the FAS, subjects will be grouped by  
randomized treatment. For other analy ses, subjects will be grouped by  actual treatment received. 
The actual treatment received will dif fer from the randomized treatment only when the actual 
treatment received differs from randomized treatment for the entire treatment duration.
The treatment groups for anal ysis are defined as follows:
VES
Placebo
However, for the overall TEAE and lab abnor mality  summary , the following treatment groups 
will be used due to dose change in protocol amendments.
VES (4 mg)
VES (4/6 mg)
VES (6 mg)
VES (6/8 mg)
VES (8 mg)
Placebo
3.3. Strata and Covariates
Randomization was stratified by  pre-ART viral load ( ≥ 50 to< 2000 copies/mL  or ≥2000 to 
≤ 5000 copies/mL ) atscreening. No covariates will be included in anal yses.
3.4. Examination of Subject Sub groups
There are no pre -specified subject subsets for efficacy  or safet y analyses.
3.5. Multiple Comparisons
All endpoint tests will be done at the significance level of 0.05 with no multiplicity  adjustment in 
this proof -of-concept study .
VES
GS-US-382-3961
Statistical Analysis Plan (Final Analysi s) Version 1.0
CONFIDENTIAL Page 16 17March 20203.6. Missing Data and Outliers
3.6.1. Missing Data
A missing datum for a given study  anal ysis window may  be due to any  of the following reasons:
A visi t occurring in the window but data were not collected or were unusable 
A visit not occurring in the window
A subject prematurel y discontinuing from the study before reaching the window
In general, values for missing data will not be imputed, unless method s for handling missing data 
are specified.
The handling of missing or incomplete dates for AE onset is described in Section 7.1.6.2, and for 
concomitant medications in Section 7.4.3.
3.6.2.
Outliers
Outliers will be identified during the d ata management and data anal ysis process, but no 
sensitivity  anal yses will be conducted to evaluate the impact of outliers on efficacy  or safet y 
outcomes, unless specified otherwise. All data will be included in the data analy ses.
3.7. Data Handling Conventions and Transformations
Laboratory  data that are continuous in nature but are less than the lower limit of quantitation
(LLOQ) or above the upper limit of quantitation ( ULOQ )will be imputed as follows except for 
urine creatinine:
A value that is 1 unit less than the limit of quantitation (LOQ )will be used to calculate 
descriptive statistics if the datum is reported in the form of “ x” (where x is considered the 
LOQ). For example, if the values are reported as < 50 and < 5.0, values of 49 and 4.9, 
respectivel y, will be used to calculate summary statistics. An exception to this rule is any 
value reported as < 1 or < 0.1, etc. For values reported as < 1 or < 0.1, a value of 0.9 or 0.09, 
respectivel y, will be used to calculate summary statistics.
A val ue that is 1 unit above the LOQ will be used to calculate descriptive statistics if the 
datum is reported in the form of “> x” (where x is considered the LOQ). Values with decimal 
points will follow the same logic as above.
The LOQ will be used to calculate descriptive statistics if the datum is reported in the form of 
“≤ x” or “≥ x” (where x is considered the LOQ).
For urine creatinine, a value of “< 1” is handled as a missing value in its summary and the 
calculation of related ratios. 
VES
GS-US-382-3961
Statistical Analysis Plan (Final Analysi s) Version 1.0
CONFIDENTIAL Page 17 17March 2020Logarithmic (base 10) transformations will be a pplied to HIV -1 RNA data for efficacy  anal yses. 
HIV-1 RNA results of ‘No HIV -1 RNA detected’ and “< 20 copies /mL HIV -1 RNA Detected” 
will be imputed as 19 copies/mL  for anal ysis purposes. 
Biomarker values that are below the limit of quant
itation ( BLQ) will be presented as “BLQ” in 
thedata listing. Values that are BLQ will be treated as LLOQ at both predose and postbaseline 
time points.
Natural logarithm transformation will be used for plasma/blood concentrations and anal ysis of 
PK parameters. Plasma concentration values that are b elow BLQ will be presented as “BLQ” in 
the concentration data listing. Values that are BLQ will be treated as 0 at pre -dose time points, 
and one -half the value of the LLOQ at postbaseline time points.
The following conventions will be used for the presentation of summary  and order statistics: 
If at least 1 subject has a concentration value of BLQ for the time point, the minimum value 
will be display ed as “BLQ.”
If more than 25% of the subjects have a concentration data value of BLQ for a given time 
point, the minimum and Q1 values will be displayed as “BLQ.”
If more than 50% of the subjects have a concentration data value of BLQ for a given time 
point, the minimum, Q1, and median values will be display ed as “BLQ.”
If more than 75% of the subjects have a concentration data value of BLQ for a given time 
point, the minimum, Q1, median, and Q3 values will be display ed as “BLQ.”
If all subjects have concentration data values of BL Q for a given time point, all order 
statistics (minimum, Q1, median, Q3, and maximum) will be display ed as “BLQ.”
3.8. Analysis Visit Windows
3.8.1. Definition of Study Day
Study  day will be calculated from the first dosing date of study  drug and derived as follows:
For postdose stud y days: Assessment Date First Dosing Date + 1
For day s prior to the first dose: Assessment Date First Dosing Date
Theref ore, study  day 1 is the day  of first dose of study  drug administration .
VES
GS-US-382-3961
Statistical Analysis Plan (Final Analysi s) Version 1.0
CONFIDENTIAL Page 18 17March 20203.8.2. Analysis Visi ts
The nominal visit as record ed on the CRF or lab date will be used when data are summarized by  
visit. Any  data relating to unscheduled visits will not be assigned to a particular visit or time 
point and will not be included in the summary  tables, but will be included in the listings.
However, the following exceptions will be made:
An unscheduled visit prior to the first dosing of study  drug may  be included in the calculation 
of the baseline value, if applicable.
Unscheduled visits after the first dose of stud y drug will be included in determining the 
maximum postbaseline toxicity  grade.
For subjects who prematurely  discontinue from the stud y, earl y termination (ET) data will be 
summarized as a separate visit, labeled as “Early  Termination Visit” .
Data obtained after the follow -up visit or last dose date plus 30 day s (whichever is later) will 
be excluded from the summaries, but will be included in the listin gs.
3.8.3. Selection of Data in the Event of Multiple Records for a Visit
Depending on the statistical anal ysis method, single values may  be required for each day . For 
example, change from baseline by  visit usually  requires a single value. 
If multiple valid, nonmissing, numeric measurements exist on the sam e nominal visit , records 
will be chosen based on the following rules if a single value is needed:
In general, the baseline value will be the last nonmissing value on or prior to the first dosing date 
of study  drug, unless specified differentl y. If multiple measurements occ ur on the same day , the 
last nonmissing value prior to the time of first dosing of stud y drug will be considered as the 
baseline value. If these multiple measurements occur at the same time or the time is not 
available, the average (arithmetic or geometric mean, as appropriate) of these measurements 
(forcontinuous data) will be considered the baseline value.
For postbaseline values
:
If there is more than one record on the selected day, the average will be taken 
(geometric mean for HIV -1 RNA and arithmetic mean for others) , unless otherwise specified .
If multiple valid, nonmissing , categorical measurements exist on the same nominal visit, records 
will be chosen based on the following rule if a single value if needed:
For baseline, the last available record o n or prior to the first dose of study
 drug will be 
selected. If there are multiple records with the same time or no time recorded on the same 
day, the value with the lowest severit y will be selected (eg, normal will be selected over 
abnormal for safet y ECG findings).
For postbaseline visits, the value for the scheduled visit only  will be used. If multiple records 
are available for a scheduled visit, the most conservative value within that day  will be 
selected (eg, abnormal will be selected over normal for safet y ECGs).
VES
GS-US-382-3961
Statistical Analysis Plan (Final Analysi s) Version 1.0
CONFIDENTIAL Page 19 17March 20204. SUBJECT DISPOSITION
4.1. Subject Enrollment and Disposition
4.1.1. Subject Enrollment
A summary  of subject enrollment will be provided by  treatment group for each country , 
investigator within a country  and overall. The summary  will present the number and percentage 
of subjects enrolled. The denominator for the percentage calculation will be the total number of 
enrolled subjects for that column. 
The randomization s chedule used for the stud y will be provided as an appendix to the clinical 
CSR.
4.1.2. Subject Disposition
The summary  of subject disposition will be provided by  treatment group and overall for all 
screened subjects. This summary  will include the number of subjects screened, screen failure 
subjects who were not randomized, subjects who met all eligibility  criteria and were not 
randomized, subjects randomized, subjects randomized but never treated, subjects in the safet y 
analysis set, and subjects in the FAS.
In ad dition, the number and percentage of the subjects in the following categories will be 
summarized:
Completed study  drug
Prematurel y discontinuing stud y drug (with summary  of reasons for discontinuing study  
drug)
Completed the study
Prematurely discontinuing from study (with summary  of reasons for discontinuing study ).
The denominator for the percentages of subjects in each category  will be the number of subjects 
in the safet y analysis set. 
No inferential statistics will be generated. A data listing of reaso ns for premature study  
drug/stud y discontinuation will be provided.
4.2. Extent of Exposure
A subject’s extent of exposure to study  drug data will be generated from the study  drug 
administration page in the eCRF. The number of doses by  VES dose level will be summarized 
using descriptive statistics.
VES
GS-US-382-3961
Statistical Analysis Plan (Final Analysi s) Version 1.0
CONFIDENTIAL Page 20 17March 20204.3. Protocol Deviations 
Protocol deviations occurring after subjects entered the study  are documented during routine 
monitoring. The number and percentage of subjects with important protocol deviations by  
deviation reason and the total number of important protocol devi ations by  deviation reason 
(eg,nonadherence to study  drug, violation of select inclusion/exclusion criteria) will be 
summarized by  treatment group for the Full Anal ysis Set. A by -subject listing will be provided 
for those subjects with important protocol deviation.
VES
GS-US-382-3961
Statistical Analysis Plan (Final Analysi s) Version 1.0
CONFIDENTIAL Page 21 17March 20205. BASELINE CHARACTERISTICS 
5.1. Demographics and Baseline Characteristics
Subject demographic data (eg, age, sex at birth, race, and ethnicity ) and baseline characteristics 
(eg, bod y weight, height , and body  mass index [BMI ]) will be summarized by  treatment group 
and overall for all cohorts combined using descriptive statistics (n, mean, SD, median, Q1, Q3, 
minimum, and maximum) for continuous data and by  the number and percentage of subjects for 
categorical data. The summaries of demographic data and baseline subject characteristics will be 
provided for the safet y analysis set.
5.2. Baseline Disease Characteristics
The following baseline disease characteristics will be summarized:
HIV-1 RNA ( log 10copies/mL )
HIV-1 RNA categories (copies/mL ) (a) < 50 and (b) ≥ 50 
CD4 cell count (/μL)
CD4+ cell count categories (/μL ): (a) <50, (b) ≥50to<200, (c) ≥ 200 to<350, (d) ≥350 to 
< 500, and (e) ≥ 500
CD4 percentage (%)
eGFR CG(mL/min)
Mode of infection (HI V risk factors)
HIV disease status
Time from HIV diagnosis to ART initiation (in years)
Duration of ART prior to study (in years)
Pre-ART HIV-RNA viral set point (log 10copies/mL)
Pre-ART HIV-RNA categories (copies/mL): (a) ≥ 50 to< 2000, (b) ≥ 2000 to≤ 5000, 
(c)>
5000
Pre-ART CD4 cell count (/μL )
Pre-ART CD4 c ell count categories (/μL ): (a) < 50, (b) ≥ 50 to < 200, (c) ≥ 200 to< 350, 
(d)≥ 350 to< 500, and (e) ≥ 500
5.3. Medical History
General medical history  data will be collected at screening and listed only . General medical 
history  data will be coded using the current version of Medical Dictionary  for Regulatory  
Activities (MedDRA).
VES
GS-US-382-3961
Statistical Analysis Plan (Final Analysi s) Version 1.0
CONFIDENTIAL Page 22 17March 20206. EFFICACY  ANAL YSES
Asthis study  is still in phase 1of the drug development, p -values from statistical compar isons 
will not be adjusted for multiplicity , so the results should be interpreted with caution. 
6.1. Definition of Efficacy Endpoints
Efficacy  endpoints include the following: 
Change from baseline in plasma log 10HIV-1RNA by  Taqman 2.0 at an y postdose timepoint
Time to virologic rebound based on 2 different cutoff values:
1) ≥ 50 copies/mL
2) ≥ 200 copies/mL
Change in plasma viral load set-point following ATI
Peak HIV -1 viral load during ATI
6.2. Statistical Hypotheses for Efficacy Endpoint s
The analysis of the efficacy  endpoints is exploratory  in nature and no formal hy pothesis testing 
was planned. 
6.3. Analysis of Efficacy Endpoint s
The full anal ysis set will be used for the efficacy  endpoint analy sis.
The change from baseline in plasma log 10HIV-1RNA by Taqma n 2.0 at any  post dose timepoint 
will be calculated for all subjects in the fullanalysis set using available on -treatment HIV
-1 
RNA data , and summarized by  treatment group using descriptive statistics (n, mean, SD, 
95% CI, median, Q 1, Q3, minimum, and maxi mum). It will also be compared between the VES 
group and the placebo group using a Wilcoxon rank sum test at a two- sided 0.05 signif icant 
level . 
Time to virologic rebound will be anal yzed using the Kaplan- Meier method . The log rank test 
will be performed to compare the difference sin the distribution of time to virologic rebound 
between the 2 treatment groups. Subjects who do not rebound will be censored at the last HIV -1 
RNA collection date during ATI period .
Change in plasma viral load set-point following ATI will be summarized and anal yzed in the 
same fashion as that of th e change from baseline in plasma log 10HIV-1RNA .
VES
GS-US-382-3961
Statistical Analysis Plan (Final Analysi s) Version 1.0
CONFIDENTIAL Page 23 17March 2020Peak HIV -1 viral load during ATI and change from baseline will be summarized and analyzed in 
the same fashion as that of the 
change from baseline in plasma log 10HIV-1RNA.
VES
GS-US-382-3961
Statistical Analysis Plan (Final Analysi s) Version 1.0
CONFIDENTIAL Page 24 17March 20207. SAFETY  ANAL YSES
7.1. Adverse Events and Deaths
7.1.1. Adverse Event Dictionary
Clinical and laboratory  adverse events (AEs) will be coded using the current version of 
MedDRA. Sy stem organ class (SOC), high- level group term (HLGT), high- level term (HLT), 
preferred term (PT), and lower -level term (LLT) will be provided in the AE dataset.
7.1.2. Adverse Event Severity
Adverse events are graded by  the investigator as Grade 1 (mild), Grade 2 (moderate), Grade 3 
(severe), or G rade 4 (life threatening) according to toxicity  criteria specified in the protocol. The 
severit y grade of events for which the investigator did not record severit y will be categorized as 
“missing” for tabular summaries and data listings. The missing catego ry will be listed last in 
summary  presentation.
7.1.3. Relationship of Adverse Events to Study Drug
Study  drug r elated AEs are those for which the investigator selected “Related” on the AE CRF to 
the question of “Related to Study  Treatment.” Relatedness will alwa ys default to the 
investigator’s choice, not that of the medical monitor. Events for which the investigator did not 
record relationship to study  drug will be considered related to study  drug for summary  purposes. 
However, b y-subject data listings will show the relationship as missing.
7.1.4. Relationship of Adverse Events to Study Procedure
Study  procedure related AEs are those for which the investigator selected “Yes” on the AE CRF 
to the question of “Related to Study  Procedures.” Relatedness will alway s default to the 
investigator’s choice, not that of the medical monitor. Events for which the investigator did not 
record relationships to study  procedure will be shown as missing from that captured on the CRF 
in by -subject data listings.
7.1.5. Serious Adverse Events
Serious adverse events (SAEs) will be identified and captured as SAEs if AEs met the definitions 
of SAE that were specified in the study  protocol. SAEs captured and stored in the clinical 
database will be reconciled with the SAE database from the Gilead Pharma covigilance and 
Epidemiology  (PVE )Department before database finalization.
VES
GS-US-382-3961
Statistical Analysis Plan (Final Analysi s) Version 1.0
CONFIDENTIAL Page 25 17March 20207.1.6. Treatment -Emergent Adverse Events
7.1.6.1. Definition of Treatment- Emergent Adverse Events
Treatment -emergent adverse events (TEAEs) are defined as one or both of the following:
Any AEs with an onset date on or after the stud y drug start date and no later than 30 days 
after permanent discontinuation of study  drug
Any AEs leading to prematur e discontinuation of study  drug
7.1.6.2. Incomplete Dates
If the onset date of the AE is incomplete and the AE stop date is not prior to the first dosing date 
of study  drug , then the month and y ear (or y ear alone if month is not recorded) of onset 
determine whether an A E is treatment emergent. The event is considered treatment emergent if 
either of the 
following 2 criteria is met:
The AE onset and end dates are the same as or after the month and year (or year) of the 
firstdosing date of study  drug
The AE onset date is the same as or before the month and year (or year) of the date 
corresponding to 30 days after the date of the last dose of study  drug
An AE with completel y missing onset and stop dates, or with the onset date missin g and a stop 
date later than the first dosing date of study  drug, will be considered to be treatment emergent.
7.1.7. Summaries of Ad verse Events and Deaths
A brief high- level summary  of TEAEs will be provided by  treatment for the number and 
percentage of subjects who had the following: any  TEAE; any  TEAE of Grade 3 or above; an y 
serious TEAE; an y stud y drug -related TEAE; an y study  drug -related serious TEAE; any  TEAE 
that led to premature discontinuation of study  drug. The treatment- emergent deaths observed 
during the stud y will also be summarized and included in this table. Treatment- emergent death 
refers to the death occurred between the first dose date and the last dose date plus 30 days, 
inclusive.
Adverse event summaries will provide the number and percentage of subjects with AEs by  SOC 
and PT, by  VES dose level based on the Safet y Analysis Set as follows:
All AEs
All AEs by  severit y
AEs of Grade 3 or above
All study -drug related AEs
VES
GS-US-382-3961
Statistical Analysis Plan (Final Analysi s) Version 1.0
CONFIDENTIAL Page 26 17March 2020All SAEs
All study -drug related SAEs
All AEs leading to premature discontinuation of study  drug
Multiple events will be counted only  once per subject per treatment in each summary . An AE 
that starts in one treatment period and continues into the following treatment period(s) will be 
counted only  in the period in which the AE began. Adverse events wil l be summarized and listed 
first in alphabetic order of SOC and then by  PT in order of descending incidence of the pooled 
treatment groups within each SOC. For summaries by  severit y, the most severe grade will be 
used for those AEs that occurred more than once in an individual subject per treatment during the 
study . 
In addition to the by -dose summaries described above, data listings will be provided for the 
following:
All AEs (with a variable indicating whether the event is treatment emergent)
SAEs
Deaths
AEs leading to premature discontinuation of study drug
7.1.8. Additional Analysis of Adverse Events
An anal ysis was performed to summarize flu- likeadverse events. This was done by  selecting a 
subset of PT sfor flu -like sy mptoms , and this list of terms was review ed by clinical. Please see 
below for the selected PTs:
Influenza
Influenza -like illness
Fatigue
Pyrexia
Chills
Myalgia
Joint pain
Headache
A summary  (number and percentage of subjects) of flu-like AE s by PT will be provided b y dose 
level based on the safet y analysis set. A data listing of flu-like AE swill be provided.
VES
GS-US-382-3961
Statistical Analysis Plan (Final Analysi s) Version 1.0
CONFIDENTIAL Page 27 17March 20207.2. Laboratory Evaluations
Laboratory  data collected during the study  will be anal yzed and summarized using both 
quantitative and qualitative methods. Summaries of laboratory data will be provided for the 
Safety  Anal ysis Set and will include data collected up to the last dose of stu dy drug plus 30 days. 
The anal ysis will be based on values reported in conventional units. When values are BLQ, they  
will be listed as such, and the imputed value will be used for the purpose of calculating summary  
statistics. 
A by -subject listing for laboratory  test results will be provided by  subject ID number and visit in 
chronological order for hematology , serum chemistry , and urinal ysis separately . Values falling 
outside of the relevant reference range and/or having a severit y grade of 1 or higher on the 
Gilead Grading Scale for Severity  of Adverse Events and Laboratory  Abnormalities will be 
flagged in the data listings, as appropriate.
No inferential statistics will be generated.
7.2.1. Summaries of Numeric Laboratory Results
Descriptive statistics will be provided b y treatment for each laboratory  test specified in the stud y 
protocol as follows:
Baseline values 
Values at each postbaseline time point
Change from baseline at each postbaseline time point
A baseline laboratory  value will be defined as the last measurement obtained on or prior to the 
date/time of first dose of study  drug. Change from baseline to a postbaseline visit will be defined 
as the visit value minus the baseline value. The mean, median, Q1, Q3, minimum, and maximum 
values will be display edto the reported number of digits; SD values will be display ed to the 
reported number of digits plus 1.
In the case of mul tiple values in an anal ysis window , data will be selected for anal ysis as 
described in Section 3.8.3 .
7.2.2.
Graded Laboratory Values
The Gilead Grading Scale for Severity  of Adverse Events and Laborator y Abnormalities will be 
used to assign toxicity  grades (0 to 4) to laboratory  results for analy sis. Grade 0 includes all 
values that do not meet the criteria for an abnormality  of at least Grade 1. For laboratory  tests 
with criteria for both increased and decreased levels, analy ses for each di rection (ie, increased, 
decreased) will be presented separatel y. If there is any lab toxicity  grading scale overlapping 
with normal reference ranges (eg, grade 1 scale overlaps with normal reference ranges), 
laboratory  values within normal range will not b e graded.
VES
GS-US-382-3961
Statistical Analysis Plan (Final Analysi s) Version 1.0
CONFIDENTIAL Page 28 17March 20207.2.2.1. Treatment -Emergent Laboratory  Abnormalitie s
Treatment -emergent laboratory  abnormalities are defined as values that increase at least 
1toxicity  grade from baseline at an y postbaseline time point, up to and including the date of 
last dose of stud y drug plus 30 days. If the relevant baseline laboratory value is missing, an y 
abnormality  of at least Grade 1 observed within the time frame specified above will be 
considered treatment emergent.
7.2.2.2. Summaries of Laboratory  Abnormalities
Laboratory  data that are categorical will be summarized using the number and percentage of 
subjects in the study  with the given response at baseline and each scheduled postbaseline time 
point .
The following summary  (number and percentage of subjects) for treatment- emergent lab oratory  
abnormalities will be provided by  lab test and treatment; subjects will be categorized according 
to the most severe postdose abnormalit y grade for a given lab test within a treatment:
Treatment -emergent laboratory abnormalities
Treatment -emergent G rade 3 and 4 laboratory  abnormalities
Treatment -emergent Grade 2, 3 ,and 4 laboratory  abnormalities
For all summaries of laboratory  abnormalities, the denominator is the number of s ubjects with 
non-missing postbaseline values up to 30 day s after last dosin g date.
A by -subject listing of treatment -emergent Grade 3 or 4 laboratory  abnormalities will be 
provided b y subject ID number and visit in chronological order. This listing will include all test 
results that were collected throughout the stud y for the la b test of interest, with all applicable 
severit y grades display ed.
7.3. Body Weight , Height, BMI and Vital Signs
Descriptive statistics will be provided b y treatment group for body weight, BMI and vital signs 
as follows:
Baseline value
Values at each postbaseline visit
Change from baseline at each postbaseline visit
In the case of multiple values in an anal ysis window, data will be selected for anal ysis as 
described in Section 3.8.3 . No formal statistical testing is planned.
VES
GS-US-382-3961
Statistical Analysis Plan (Final Analysi s) Version 1.0
CONFIDENTIAL Page 29 17March 2020A by -subject listing of vital signs will be provided by  subject ID number and visit in 
chronological order. In the same manner, a b y-subject listing of body  weight, height, and BMI
will be provided separately .
7.4. Prior and Concomitant Medications
Medications collected at screening and during the study  will be coded using the current version 
of the Gilead- modified World Health Organization (WHO) Drug dictionary .
All prior and concomitant medications (other than per -protocol study  drugs) will be provided in a 
by-subject listing sorted by  subject ID number and administration date in chronological order.
7.4.1. Antiretroviral Medications
Any ARV medications used prior to, during, or after the study  (if collected) are all recorded on 
the ARV eCRF. All ARV medications recorded on the ARV eCRF will be coded using the
Gilead- modified WHO Drug Dictionary for ARV medication. The WHO preferred name and 
drug code will be attached to the clini cal databa se. All ARV medications recorded on the ARV 
eCRF will be listed. No inferential statistics will be provided.
7.4.2. Prior Antiretroviral Medications
Prior ARV medications are defined as ARV medications taken on or up to 2 day s prior to the 
first dose date of randomized study  drug based on
ARVs reported on ARV eCRF.
7.4.3. Concomitant Non -Antiretroviral Medications
Concomitant non-ARV medications (ie, non-ARV medications other than study  drug that are 
taken while receiving study  drug) will be coded using the WHO Drug Dictionary . The WHO 
preferred name and drug code will be attached to the clinical database. Use of concomitant 
medications will be summarized (number and percentage of subjects) b y treatment group, WHO 
drug class and preferred name. Multiple drug use (by  preferred name) will be counted onl y once 
per subject. The summary  will be sorted alphabetically  by drug class and then by  decreasing 
total 
frequency  within a class.
If the start or stop date of non-ARV medications is incomplete, the month and y ear (or year 
alone, if month is not recorded) of the start or stop date will be used t o determine whether the 
non-ARV medications are concomitant or not. The medication is concomitant if the month and 
year of the start or stop (or y ear of the start or stop, if month 
is not recorded) of the medication 
does not meet either of the following criteria:
The month and y ear of start of the medicatio n is after the last dose date
The month and year of stop of the medication is before the first dose date
VES
GS-US-382-3961
Statistical Analysis Plan (Final Analysi s) Version 1.0
CONFIDENTIAL Page 30 17March 2020If the star t and stop da te of non-ARV medications are complete, the start date is not after the 
lastdose date and the stop date is not before the first dose date, or the non - ARV medications are 
marked as ongoing and start date is on or before the last dose date, the non-ARV medications are 
concomi tant for the study .
Summaries of non-ARV concomitant medications will be provided for the safet y analysis set. 
Subjects with any  non- ARV concomitant medications will be listed. No inferential statistics will 
be provided
.
7.5. Electrocardi ogram Results
Electrocardiogram (ECG) data will not be presented in the CSR since ECGs were not assessed in 
this study  other than as part of the screening process for potential new subjects.
7.6. Other Safety Measures
A by -subject listing of subject pregnancies during the study  will be provided by  subject ID 
number. No additional safety measures are specified in the protocol.
Although not necessaril y related to safet y, a b y-subject listing of all comments received during 
the study  on the comments form will be pr ovided by  subject ID number, and form for which the 
comment applies.
7.7. Changes From Protocol -Specified Safety Analyses
There are no deviations from the protocol-specified safet y analyses.
VES
GS-US-382-3961
Statistical Analysis Plan (Final Analysi s) Version 1.0
CONFIDENTIAL Page 31 17March 20208. PHARMACOKINETIC ANAL YSES
8.1. PK Sample Collection
Plasma VES concentrations will be collected at the following time points:
Pre-dose ( ≤ 5 minutes prior to dosing), 0.5, 1, 2 , 4, 6, 8, 10, and 24 hours post dose a t Dose 
1-Day 1 visit.
8.2. PK Analyses Related to Intensive PK Sampling
VES PK parameters will be determined in subjects in the VES PK analy sis set. Concentrations of 
VES in plasma will be determined using validated bioanaly tical assay s.
8.2.1. Estimation of Pharmacokinetic Parameters
PK parameters will be estimated using Phoenix WinNonlin®software using standard 
noncom partmental methods. The linear/log trapezoidal rule will be used in conjunction with the 
appropriate noncompartmental model, with input values for dose level, dosing time, plasma 
concentration, and corresponding real -time values, based on drug dosing times whenever 
possible.
All predose sample times before time -zero will be converted to 0 . 
For area under the curve (AUC), samples BLQ of the bioanal ytical assay s occurring prior to the 
achievement of the first quantifiable concentration will be assigned a concentration value of 0 to 
prevent overestimation of the initial AUC. Samples that are BL Q at all other time points will be 
treated as missing data in WinNonlin®. The nominal time point for a key  event or dosing interval 
(τ) may  be used to permit direct calculation of AUC over specific time intervals. The 
appropriateness of this approach will be assessed by  the PK scientist on a profile -by-profile 
basis.
Pharmacokinetic parameters such as AUC inf, λzand t 1/2 are dependent on an accurate estimation 
of the terminal elimination phase of drug. The appropriateness of calculating these parameters 
will be evaluated upon inspection of PK data on a profile -by-profile basis by  the PK scientist.
8.2.2. PK Parameters
Pharmacokinetic parameters will be generated for all subjects for whom parameters can be 
derived. The primary  PK parameters are AU Clast, AUC inf, and CmaxofVES .
Table 8-1. PK Parameters for VES
Analyte Param eters
VES Cmax, Tmax, Clast, Tlast, AUC last,AUC inf, %AUC exp, T1/2, Vz/F, CL/F, and   
VES
GS-US-382-3961
Statistical Analysis Plan (Final Analysi s) Version 1.0
CONFIDENTIAL Page 32 17March 20208.3. Statistical Analysis Methods
Individual subject concentration data and individual subject PK parameters of VES will be listed 
and summarized for subjects in the VES PK anal ysis set by  treatment. Summ ary statistics 
(n,mean, SD, coefficient of variation [CV(%)], minimum, median, maximum, Q1, Q3) will be 
presented . The number of subjects with concentration values BLQ will be presented. The 
geometric mean, geometric mean 95% CI, and the mean and SD of the natural log -transformed 
values will be presented for all PK parameters in addition to the summaries men tioned above.
Plasma concentrations over time will be plotted in the semi- logarithmic and linear scale as mean 
± SD, and median (Q1, Q3) b y treatment. In addition, individual subject plasma concentrations 
over time will be plotted by  treatment group. 
VES
GS-US-382-3961
Statistical Analysis Plan (Final Analysi s) Version 1.0
CONFIDENTIAL Page 33 17March 20209. PHAR MACODYNAMIC (PD) ANAL YSES
9.1. Definition of PD Endpoints
PDendpoints include the following:
Change , percentage change and fold change from baseline in the levels of serum cytokines 
(including IFN -, IL-1RA, I P-10, and ITAC)
Fold change in mRNA for I SGs inclu ding MX1, OAS1 and I SG15
9.2. Analysis of PD Endpoints
The full anal ysis set will be used for other efficacy endpoint anal ysis. 
Change ,percentage change and fold change from baseline (postbaseline/baseline) in the levels of 
serum cy tokines will be summarized by  treatment group using descriptive statistics and 
compared between each active treatment group and the pooled placebo group using a Wilcoxon 
rank sum test at a two -sided 0.05 significant level.
Fold change from baseline (postbaseline/baseline) in mRNA for ISGswill be anal yzed similarly  
as above.
VES
GS-US-382-3961
Statistical Analysis Plan (Final Analysi s) Version 1.0
CONFIDENTIAL Page 34 17March 202010. REFERENCES
Smith BP, Vandenhende FR, DeSante KA, Farid NA, Welch PA, Callaghan JT, et al. Confidence 
interval criteria for assessment of dose proportionality . Pharm Res 2000;17 (10):1278-83.
U.S. Department of Health and Human Services Food and Drug Administration Center for Drug 
Evaluation and Research (CDER). Guidance for Industry . Statistical Approaches to 
Establishing Bioequivalence.  January , 2001.
U.S. Department of Health and Human Services Food and Drug Administration Center for Drug 
Evaluation and Research (CDER). Guidance for Industry . Bioavailability  and 
Bioequivalence Studies for Orall y Administered Drug Products - General Considerations 
(Revision 1).  March, 2003.
VES
GS-US-382-3961
Statistical Analysis Plan (Final Analysi s) Version 1.0
CONFIDENTIAL Page 35 17March 202011. SOFTW ARE
SAS®Software Version 9.4. SAS I nstitute Inc., Cary , NC, USA.
Phoenix WinNonlin. Version 7.0 Certara. Princeton , NJ.
VES
GS-US-382-3961
Statistical Analysis Plan (Final Analysi s) Version 1.0
CONFIDENTIAL Page 36 17March 202012. SAP REVISION
Revisio n Date
(DD MMM YYYY ) Section Summary of Revision Reason for Revision
VES
GS-US-382-3961
Statistical Analysis Plan (Final Analysi s) Version 1.0
CONFIDENTIAL Page 37 17March 202013. APPENDICES 
Appendix 1. PK Parameters
PK parameters evaluated in this study  are listed below.
Param eter Description
AUC lastarea under the concentration versus time curve from time zero to the last quantifiable 
concentration
AUC infarea under the concentration versus time curve extrapolated to infinite time, calculated as AUC 0-
last(Clast/z)
%AUC exp Percentage of AUC extrapolated betw een AUC 0-last and AUC inf
Clast last observed quantifiable concentration of the drug in plasma
Cmax maximum observed concentration of drug in plasma
CL/Fapparent oral clearance after administration of the drug: 
at single dose: CL/F =Dose/AUC inf , where “Dose” is the dose of the drug
at steady state: CL/F =Dose/AUC tau, where “Dose” is the dose of the drug
T1/2estimate of the terminal elimination half -life of the drug in plasma, calculated by dividing the 
natural log of 2 by the terminal elimination rate constant ( z)
Tlast time (observed time point) of C last
Tmax time (observed time point) of C max
Vz/F apparent volume of distribution of the drug
zterminal elimination rate constant, estimated by linear regression of the terminal elimination 
phase of the plasma concentration of drug versus time curve
The following plasma PK parameters of VES will be calculated:
Cmax, Tmax, Clast, Tlast, z, T1/2, AUC last, AUC inf, %AUC exp, Vz/F, and CL/F .
VES
GS-US-382-1450
Statistical Analysis Plan (Final Analysi s) Version 1.0
CONFIDENTIAL Page 38 17March 2020Appendix 2. Schedule of Assessments
VisitPeriod 1v,w P2
P Period P3 P2 or P3Screening a
Day -13
Dose 1 -Day 1
Dose 1-Day 2
Dose 1-Day 8
Dose 2- Day 1
Dose 2-Day 8
Dose 3 Day 1
Dose 3-Day 8
Dose 4 Day 1
Dose 4-Day 2
Dose 4-Day 4 Dose 4-Day 8
Dose 5 Day 1
Dose 5-Day 8
Dose 6 Day 1
Dose 6-Day 4 Dose 6-Day 8
Dose 7 Day 1
Dose 7-Day 8
Dose 8 Day 1
Dose 8-Day 8
Dose 9 Day 1
Dose 9-Day 8
Dose 10 Day 1
Dose 10-Day 2 Dose 10-Day 4 Dose 10-Day 8
Dose 10-Day 14
ATI Visit 1p
Visits 2-24q,x
ATI Remission r
End of Studyt
ART Re-initiation Visitsx
Post ART re-suppression Visits 
1-6z
ESDDu Informed 
ConsentX
Medical 
Historyb X X X
Pre-ART viral 
load set pointX
HLA Class I and 
II type , 
pre-ART CD4 
Nadir, historical 
genotypeX
AE and Con 
Medso X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X
Complete 
Physical ExamX X XhX
Symptom  
Directed 
Physical ExamX X X X X X X X X X X X X X X X X X X X X X X X X X X X XiX X X
12-Lead ECG X
Vital Signs X X X X X X X X X X X X X XjX X X X X
Weight X X X X X X X X X X X X X XjX X X X
Height X
Review of I/E 
criteriac X
Rando mization X
CCI
YES 
GS-US-382-1450 
Statistical Analysis Plan (Final Analysis) 
N 00 00 ... >. >. >. >. >. " " " 'ii " " Q " · a ! ! >. " * * * * * Q u Q Q Q Q Q U) Q Q Q Q Q Period r,w 
00 N ... 00 00 
>. >. >. >. >. >. >. >. " " " " " " " " Q 'ii Q Q ..., ..., ... "' * Q 
Q * Q 
Q * Q 
Q * Q 
Q * Q 
Q * Q 
Q * Q 
Q * Q 
Q P2 
P Period 
... 00 00 00 00 N ... 00 :?: ::. :. >. >. >. >. >. >. >. >. >. >. >. >. >. >. " " " " ... " " " " " " " " " Q Q Q Q " N Q Q Q Q 'ii Q Q Q 'ii ,.., '° '° ... ... 00 al, 0- > * * * * * * * * * i== * * * Q Q Q Q Q Q Q Q Q > Q Q Q Q Q Q Q Q Q Q Q Q Q Q < Q Q Q Q Q -------------------------------
Urinalysis X X X X X X X X X X X X x• 
Urine Pref,'tla ncy X X X X X X X X X X X X X' Test• 
Blood colleclioo for 
Chemistry X X X X X X X X X X X X x• 
Hemato logy X X X X X X X X X X X X x• 
Metabo lic X asscss mcnte 
cGFR X X X x• 
Scrum X Pref,'tla ncy Test• 
CD4+ccll 
count,CD8 + 
cell count, X X X X X X X X X X X X X X 
CD4K:D8 ratio 
andCD4 % 
HBV /HCV X Scrologyf 
GS-9620 X X Intensive PK• 
Plasma ART PK X X X"' 
CONFI DENT IAL Page 39 Version 1.0 
P2 or P3 
· ! > 
" >. > .:: 
" E "! Q Q Y} . ., 
8:fc - ~ Q .... · a :, ' Q 'I'-
"' 'J; t " "" c,: ... ... c,: 
c,: < < 
X X 
X X' X X 
X X 
X X 
X 
X X X X 
17 March 2020 
YES 
GS-US-382-1450 
Statistical Analysis Plan (Final Analysis) Version 1.0 
Period r,w P2 
p Period P2 or P3 
· ! > 
" N 00 00 00 N ... 00 00 ... 00 00 00 00 N ... 00 :?: >. > .:: ... >. >. >. >. >. >. >. >. >. >. >. >. >. >. >. >. >. >. >. >. >. >. >. >. >. >. >. ::. :. "! " E " " " " " " ... C " 'ii " " Q " " " " " " " " " " " " " " " " " " Q Q Q Q " N . ., Q · a ! ! Q 'ii Q Q Q Q Q Q 'ii Q Q Q 'ii > Y} - ~ 8:fc Q >. ..., ..., ... "' ,.., '° '° ... ... 00 al, 0- .... · a :, ' " * * * * * * * * * * * * * * * * * * * * * * i== C 'I'-
u Q * * * "' 'J; t C C C C C C C C C C C C C C C C C C C C C C > " U) Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q C C C C C < "" c,: Q Q Q Q Q ... ... c,: 
c,: < < ,;; 
C 
Visit .. 
TLR 7 X gcnotyping 
Pla sma HJV-1 
RNA by X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X 
Taqman 2.0 
HJV -1 
Gcno typc/Phcno 
type .. 
VAS X X X Questionnaire 
Pla sma HJV-1 
X X X X X X X X X X X xu 
RNA by SCA 
PBM C 
X X X X X X X X X X X xu 
. • I . 
. . I •••••••••••••••••••••••••••••• ··-
I II II 
Cyto kincs, 
chcmok incs 
Teel! !CS X 
CONFI DENT IAL X X X X 
X X X X X X X X 
X X X X X X 
X X 
Page 40 17 March 2020 
YES 
GS-US-382-1450 
Statistical Analysis Plan (Final Analysis) Version 1.0 
P2 Period r,w P Period P2 or P3 
N 00 00 00 N ... 00 00 ... 00 00 00 00 ... >. >. >. >. >. >. >. >. >. >. >. >. >. >. >. >. >. >. >. >. >. >. >. 
" " " " 'ii " " Q " " " " " " " " " " " " " " " " " " Q · a ! ! Q 'ii Q Q Q Q Q Q 'ii Q Q Q 
>. ..., ..., ... "' ,.., '° '° ... ... 00 al, 0-" * * * * * * * * * * * * * * * * * * * * * * Q u Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q U) Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q 
Q 
Visit 
Immune cell 
activation, X X X 
phcno typing 
X 
.. ••----------------------
X X X X X X N ... 00 :?: >. >. >. >. " " " Q Q Q " 'ii 
* Q 
Q * Q 
Q * Q 
Q Q 
Q 
X 
X ::. :. ... 
N 
> 
i== > < >. 
"! 
Y} .... 
Q 
"' " "" · ! > 
" > .:: 
" E Q . ., 
8:fc - ~ · a :, ' 'I'-
'J; t c,: ... ... c,: 
c,: < < ,;; 
Q .. 
I I ---------------- ------In-Clinic 
DosingY X X X X X X X X X X 
a Evaluations to be comp leted within 35 days prior to Pre Base line/Day 13 
b Med ical history includ ing route and estimated durat ion of HIV I infect ion, history of HIV I disease related events , anti retrov iral treatment (ART) history for at least 6 months and prior 
med ications within 35 days of the screen ing visit 
c If subject's ART regimen is changed 2:: 45 days prior to Base line/Dose I Day I, plasma HIV I RNA <50 copies/mL at Pre base line/Day 1 3 visit is re.qu ired to confim1 eligibility. 
d Fema les of childbear ing potent ial on ly. Positive urine pregnancy tests will be confim1ed with a serum test. 
e Fasting (no food or drinks, except water , at least 8 hours prior to blood collection) glucose and lipid pane l (tota l cho lestero l, HDL , direct LDL , triglycerides). If the subject has not fasted prior to 
the visit, the visit may proceed , but the subject must return within 72 hours in a fasted state to draw blood for the metabo lic assessments. 
f HBV blood pane l will be perfom1ed at Screening (Hepat itis B vi rus surface antigen (HBsAg) , Hepat itis B vi rus surface antibody (HBsAb) and Hepat it is B vi rus core antibody (HBcAb)). 
Hepat itis C antibody (HCVAb) will be perfom1ed. Q 
Q 
CONFIDENTIAL Page 41 17 March 2020 
YES 
GS-US-382-1450 
Statistical Analysis Plan (Final Analysis) 
g Intens ive PK samp les will be collected at Pre dose (::S 5 mi nutes prior to dosing), 0.5, I, 2, 4, 6, 8, IO and 24 hours post dose at Dose I Day I visit. 
h Comp lete phys ical exam ination at visits 5, 9, 1 3, 1 7, 2 1 , 26, 28, 30, 32, 34, 36 
Symptom directed phys ical exam ination as needed at visits 3, 7, 11, 1 5, 1 9, 23, 25, 27, 29, 3 1 , 33, 35 
j Vi tal signs and weight at visits 3,5, 7,9, 11, 1 3, 1 5, 1 7, 1 9,2 1 , 23. 
k Chem istry, Hemato logy, eGFR and Urinalysis at visits 5, 9, 1 3, 1 7, 2 1 , 26, 28, 30, 32, 34, 36 Version 1.0 
I U rine pregnancy test at visits 3,5,7,9, 11, 1 3, 1 5, 1 7, 1 9,2 1 ,23. Urine pregnancy test will also be done at first ART re initi ation visit and month ly thereafter until Post ART re supp ression Visits 
m During the Pre Base line/Day 1 3, Dose IO Day 14, and AT! Rem ission visits, 110 ml of blood will be drawn. At Dose 6 Day I and Post ART Re Supp ression Visit 6, only 20 ml of blood will be 
drawn r 
o ya verse event or tests owing abnorn1a l results that is believed to have a poss ible or probab le causa l relationsh ip wi th the study dmg will be repeated week ly (or as often as deemed pmdent 
by the Invest igator) until the abnorn1a lity is resolved, returns to base line, or is otherw ise explained. 
p AT! Visit I to occur at Dose 1 0 Day 28 for subjects with HIV I RNA <50 copies/mL at Dose 1 0 Day 1 4 visi t. For subjects with viral load >50 copies/mL at Dose 1 0 Day 14 - I load is achieved within two re test measu rements. Subjects to discont inue study medication and ART from AT! Visit I throug h AT! Visit 24 
q Week ly v1 s1 ts 2 24 
r This visit w ill be planned after comp letion of 12 weeks of AT! for subjects with plasma HIV I RNA <50 copies/mL in the absence of ART re initi ation. If subjects have HIV I viral load 
<50 copies/mL at AT! Visit 12, the visit shou ld occu r within a week of A TI Visit 1 2. However , if the subject does not have HIV I viral load <50 copies/mL at AT! Visit 12, this visit may still 
occur at a later time point between AT! Visit 1 3 once the HIV I viral load <50 copies/mL. 
r • End of study visit to occur 7 days (± I day) after the last AT! Visit if subject has not re initiated ART during Period 2 and 3. 
u Early Study Dmgs Discont inuation visit is re.qu ired if subject discont inues study medication prior to comp letion of Dose I 0. The visit to occu r within 30 days of last dose of study dmg. 
v If HIV I RNA viral load will be >5000 copies/mL at any visit post Dose , viral load will be observed at next schedu led visit or r etested within 4 days. The next dose will be withheld and only 
given if viral load of:::; 5000 copies/mL is achieved. The study procedu re schedu le will be reset relative to the next dose of GS 9620. 
w If plasma vims HIV I RNA levels are > 5000 copies/mL at third retest visit during a single dosing period, then this subject will be cons idered to have confirnied virologic failure and blood 
samp les from this visit w ill be used for HIV I enot e/ henot e testing with assays correspond ing to the antiretrov iral medications the subject is taking. 
x During Visits 2 24 in Period 2 , ART will be re initi ated if subject meets the criteria defined in the protoco l. Once ART is re initiated, week ly visi ts 
(ART Re initiation visits) will occu r to measu re plasma viral load and CD4 + count will be conducted until plasma viral load becomes undetectab le (< 50 copies/mL), and then every other week 
until two consecut ive measures are undetectab le. 
y Dosing to occu r in fasting state. Food not pern1itted 2 hours prior to and 2 hours after dosing. Overnight fasting is preferab le. Aside from 240 mL wate r prov ided at dosing, water /liquid not to be 
pern1itted from I hour prior to until 2 hours after dosing. Subjects to prov ide inforn1at ion on food consumpt ion and total fasting time prior to dosing. 
z Post ART Re supp ression visits is applicable for subject(s) who re initi ates ART during AT!. The visit to occu r month ly for six months after subject has achieved HIV I RNA of <50 copies/mL 
at two consecut ive visits. A wi ndow of± 6 days may be used to schedu le this visit 
aa To be perfornied at Post ART Re supp ression Visit 6 only 
bb HIV I genotype and phenotype testing for subjects with prolonged Viremia. Refe r to the protoco l for retest ing and st~ 
cc Additional PK samp les may be drawn to verify that subject continues being off ART during the AT! phase (Period 2---- )-Samp les will be drawn upon Sponsor re.quest 
depend ing on the subject's HIV I RNA levels 
CONFIDENTI AL Page 42 17 March 2020 
VES
GS-US-382-1450
Statistical Analysis Plan (Final Analysi s) Version 1.0
CONFIDENTIAL Page 43 17March 2020Appendix 3. Programming Specification
1)
AGE calculated as follows:
a)AGE (y ears) is calculated from the number of day s between the date of birth (DOB) 
and Day  1 (first dose date),
b) Use the SAS INTCK function to determine the number of “1st-of-month day s” 
(eg,January  1st, February  1st, March 1st) between DOB and Day  1 (inclusive),
c)Divide the result in (b) by 12,
d)AGE  the integer of the result in (c),
e)If the DOB and Day  1 have the month in common and the birthday is later in the 
month than the date of Study  Day  1, then subtract one from the AGE result above.
For subjects randomized and never dosed with study  drug, age will be calculated from the 
date of randomization.
2)All screened subjects refer to all subjects who are screened (ie, wit h nonmissing 
screening date) and have a screening number. For summaries, the same subject is counted 
only once. DOB and other demographic information such as sex, race, ethnicity , country , 
and initials will be used to identify  unique screened subjects.
3) Scr een failure subjects are the subjects who are screened and answered “No” for an y 
inclusion criteria or “Yes” for an y exclusion criteria regardless of which version of 
protocol the subject was consent to. 
4)Subjects in the randomized anal ysis set are defined as subjects randomized into the study . 
IXRSRAND is the source to determine whether the subject is randomized (ie, subject 
with nonmissing RGMNDTN in the IXRSRAND dataset) and confirmed by the eCRF 
ENROLL dataset (ie, ENROLLYN  “Yes” in ENROLL dataset).
5) R andomized treatment (ie, TRT01P in ADSL ) are derived from IXRSRAND, while 
actual treatment received (ie, TRT01A in ADSL) is assigned as the randomized treatment 
if subject took at least 1 dose of study  drug and assigned as blank if subject never dosed.
6)In disposition table, the reasons for premature discontinuation are display ed in the order 
as they  appear on the eCRF.
VES
GS-US-382-1450
Statistical Analysis Plan (Final Analysi s) Version 1.0
CONFIDENTIAL Page 44 17March 20207)Body mass index (BMI) and Bod y Surface Area (BSA)
BMI and BSA will be calculated onl y at baseline as follows:
BMI  (weight [kg]) / (height [meters]2)
BSA (m2)  SQRT( [Height(cm) × Weight(kg) ] / 3600 )
Baseline height and weight will be used for this calculation. 
8) Please note, “Not Permitted”, “Unknown”, or missing categories will be excluded for 
percentage calculation. Except for Mode of infection (HIV Risk Factors), where 
“Unknown” will be included for percentage calculation, since a subject may fit more than 
1HIV risk factors, therefore percentage may  add to more than 100% and no p -value will 
be generated. 
Subjects with Race  “Not Permitted” will also be exclud ed to define Race subgroup 
(ie,black vs. nonblack) for efficacy  subgroup analy sis. 
9)Last Dose Date and Last Study  Date
a)Last Dose Date (ie, TRTEDTC, TRTEDT, TR01EDT or TR01EDTC) in ADSL  was 
defined in Section 3.8.1 .
For subjects with a partial last dosing date (ie, month and y ear of last dose are 
known), the latest of the dispensing dates of study drug bottles, stud y drug start dates 
and end dates, and the imputed last dose date [day  imputed as 15] will be used as the 
final imputed last dose date. However if dispensing date’s month is after last dose 
date’s month, data query  is needed.
If subject died and the death date is complete (ie, not pa rtial date) and before the 
imputed last dose date, the complete death date should be used as the imputed last 
dose date. 
b)Last Stud y Date is the latest of the study  drug start dates and end dates, the clinic visit 
dates, and the laboratory  visit dates, inc luding the 30- day follow -up visit date, for 
subjects who prematurely  discontinued study  or who completed study  according to 
the Study  Completion eCRF. If study  drug start dates or end date is partially  missing 
(ie,only year and month are known), the day  will be imputed as 15 for the purpose of 
this analy sis.
If subject died and the death date is complete (ie, not partial date) and before the 
imputed last study  date, the complete death date should be used as the imputed last 
study  date. 
VES
GS-US-382-1450
Statistical Analysis Plan (Final Analysi s) Version 1.0
CONFIDENTIAL Page 45 17March 202010)Toxicity  Grades:
a)For toxicity  grade summaries, include all post baseline graded results up to 30 days 
after the last dose of study  drug, not just those used in by -visit summaries.
b)For glucose grading,the treatment
-emergent flag cannot be determined for nonfasting 
glucose (including glucose results without a known fasting status ). As a result, these 
records will be excluded from the “Maximum Treatment -emergent Toxicity  Grade” 
summary  in the “Treatment -emergent Laboratory  Abnormalities” or 
“Treatment -emergent Grade 3 or 4 Laboratory  Abnormalities” summary  tables. I n 
addition, fasting glucose and nonfasting glucose will be listed as two separate 
laboratory  tests in the “Laboratory  Abnormalities” and “Grade 3 or 4 Laboratory  
Abnormalities” listings. Only a maximum postbaseline toxicity  flag will be display ed 
and the treatment -emergent flag will not be display ed for nonf asting glucose as the 
treatment -emergent flag cannot be dete rmined for nonfasting glucose. 
11)TEAE
Events with Missing Onset Day and/or Month
An AE is treatment emergent if the following 3 criteria are met:
The month and y ear (or year) of onset date is the same as or after the month and y ear 
(or year) of the first dose of study drug, and
The month and y ear (or year) of the onset date is the sa me as or before the month and 
year (or y ear) of the 30th day  after the date of the last dose of study  drug, and
End date is as follows: 
a.The (complete) end date is on or after the first dose date, or
b.The month and year (or year) of end date is the same or after the month and y ear 
(oryear) of the first dose of study drug, or
c.End date is completel y missing 
Events with Completely Missing Onset Date
An AE with a completel y missing onset date is defined as TEAE if end date meets an y of 
the criteria specified in 3) above.
VES
GS-US-382-1450
Statistical Analysis Plan (Final Analysi s) Version 1.0
CONFIDENTIAL Page 46 17March 202012)PK parameters at the individual subject level should be displayed with the following 
reported number of decimal places:
LambdaZ, r2, r2 adj, and CORRXY: 3 decimal places
t1/2, Tlast, Tmax, BEGHOUR, and ENDHOUR: 2 decimal places
AUCtau, AUC0- last, AUCinf, %otAUCexp, Vz/F, CL /F, CLss/F, Cmax, Clast and 
Ctau: 1 decimal place
NPOINTS: 0 decimal place
PK concentration data will be reported with 1 decimal place. 
13)Concomitant nonstudy -drug ARV medications (ie, ARV medications other than study  
drug that are taken while receiving stud y drug) will be flagged in “Nonstudy -Drug 
Antiviral Medication” listing. The logic to define concomitant nonstudy -drug ARV is 
similar to concomitant non- ARV Medications (see details in Section 7.4.3)
14)For biomarker data, s
tudy day will be calculated from the first dosing date of study  drug 
and derived as follows:
Forpostdose study  days: Collection Date First Dosing Date + 1
For day s pri
or to the first dose: Collection Date First Dosing Date
Theref ore, study  day 1 is the day  of first dose of study  drug administration .
15)Time from HIV diagnosis to ART initiation (in y ears) is calculated as (the date ART 
started - date subject was diagnosed with HIV disease)/365.25. 
The duration of ART prior to study  (in years) is calculated as (first dose date -date 
subject first start ART)/365.25. 
For the date subject was diagnosed with HIV disease and date subject first start ART, 
missing dates will be imputed. If onl y the date is missing, it is imputed as 15. If both 
month and date are missing, it will be imputed as July  1st.
16)Virologic rebound
The virologic rebound ≥50 copies/mL is defined as two consecutive HIV -1 RNA 
measurement ≥ 50 copies/mL .The date of rebound is the first time HIV-1 RNA 
measurement ≥ 50 copies/mL . 
The virologic rebound ≥200 copies/mL is defined as two consecutive HIV -1 RNA 
measurement ≥ 200 copies/mL . The date of rebound is the first time HIV-1 RNA 
measurement ≥ 200 copies/mL . 
Time to virologic rebound (in weeks)  (date of rebound -date of first ATI visit +1)/7.
VES
GS-US-382-1450
Statistical Analysis Plan (Final Analysi s) Version 1.0
CONFIDENTIAL Page 47 17March 202017)Change in plasma viral load set -point following ATI  viral set-point following ATI 
pre-ART set point
The plasma viral set -point following ATI is calculate d as the geometric mean of all the 
HIV-1 RNA measurements between a start date and an end date. The start date and end 
date will be provided b y clinical based on blinded individual subject data review. For 
Pre-ART set point, we will use the value if only  one value is recorded in the clinical 
database. If there are multiple values recorded, we will use the geometric mean.
18)Peak HIV -1 viral load during ATI
For subjects who did not restart ART, the maximum value of HIV -1 RNA 
measurements during ATI is used as the peak value.
For subjects who restarted ART, the maximum value of HIV -1 RNA measurements 
during AT I before the restart of ART is used as the peak value.
GS-382-3961 Final Analysis SAP
ELECTRONIC SIGNATURES
Signed by Meaning of Signature Server Date
(dd-MMM-
yyyy hh:mm:ss)
Clinical Research eSigned 17-Mar-2020
19:26:27
Biostatistics eSigned 17-Mar-2020
19:29:05
PPD
PPD